276 related articles for article (PubMed ID: 26916314)
1. The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis.
Sartori M; Favaretto E; Migliaccio L; Guazzaloca G; Legnani C; Palareti G; Cosmi B
Thromb Res; 2016 Mar; 139():154-7. PubMed ID: 26916314
[TBL] [Abstract][Full Text] [Related]
2. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.
Morris TA; Castrejon S; Devendra G; Gamst AC
Chest; 2007 Oct; 132(4):1131-9. PubMed ID: 17646239
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin-induced thrombocytopenia in a child.
Dager WE; White RH
Ann Pharmacother; 2004 Feb; 38(2):247-50. PubMed ID: 14742760
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).
Cosmi B; Filippini M; Campana F; Avruscio G; Ghirarduzzi A; Bucherini E; Camporese G; Imberti D; Legnani C; Palareti G;
Thromb Res; 2014 Feb; 133(2):196-202. PubMed ID: 24365043
[TBL] [Abstract][Full Text] [Related]
5. Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia.
Gleichgerrcht E; Lim MY; Turan TN
Neurologist; 2017 Nov; 22(6):241-244. PubMed ID: 29095327
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
Cosmi B; Filippini M; Tonti D; Avruscio G; Ghirarduzzi A; Bucherini E; Camporese G; Imberti D; Palareti G;
J Thromb Haemost; 2012 Jun; 10(6):1026-35. PubMed ID: 22487001
[TBL] [Abstract][Full Text] [Related]
7. Incidence and diagnosis of heparin-induced thrombocytopenia (HIT) in patients with traumatic injuries treated with unfractioned or low-molecular-weight heparin: a literature review.
Bloemen A; Testroote MJ; Janssen-Heijnen ML; Janzing HM
Injury; 2012 May; 43(5):548-52. PubMed ID: 21640991
[TBL] [Abstract][Full Text] [Related]
8. Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.
Rabe E; Hoffmann U; Schimke A; Heinken A; Langer F; Noppeney T; Pittrow D; Klotsche J; Gerlach HE; Bauersachs R;
Eur J Vasc Endovasc Surg; 2023 Nov; 66(5):697-704. PubMed ID: 37573936
[TBL] [Abstract][Full Text] [Related]
9. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).
Bauersachs R; Gerlach HE; Heinken A; Hoffmann U; Langer F; Noppeney T; Pittrow D; Klotsche J; Rabe E
Eur J Vasc Endovasc Surg; 2021 Aug; 62(2):241-249. PubMed ID: 34210599
[TBL] [Abstract][Full Text] [Related]
10. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
[TBL] [Abstract][Full Text] [Related]
11. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).
Rota E; Bazzan M; Fantino G
Thromb Haemost; 2008 Apr; 99(4):779-81. PubMed ID: 18392338
[No Abstract] [Full Text] [Related]
12. The management of heparin-induced thrombocytopenia.
Keeling D; Davidson S; Watson H;
Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
[TBL] [Abstract][Full Text] [Related]
13. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Warkentin TE; Greinacher A
Chest; 2004 Sep; 126(3 Suppl):311S-337S. PubMed ID: 15383477
[TBL] [Abstract][Full Text] [Related]
14. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis.
Randi ML; Tezza F; Scapin M; Duner E; Scarparo P; Scandellari R; Fabris F
Acta Haematol; 2010; 123(3):140-5. PubMed ID: 20134155
[TBL] [Abstract][Full Text] [Related]
15. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?
Levine RL; McCollum D; Hursting MJ
Chest; 2006 Sep; 130(3):681-7. PubMed ID: 16963663
[TBL] [Abstract][Full Text] [Related]
16. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.
Lindhoff-Last E; Nakov R; Misselwitz F; Breddin HK; Bauersachs R
Br J Haematol; 2002 Sep; 118(4):1137-42. PubMed ID: 12199798
[TBL] [Abstract][Full Text] [Related]
17. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
Lobo B; Finch C; Howard A; Minhas S
Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
[TBL] [Abstract][Full Text] [Related]
18. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery.
Bucci C; Geerts WH; Sinclair A; Fremes SE
Am J Cardiol; 2011 Feb; 107(4):591-4. PubMed ID: 21184996
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II].
Ganzer D; Gutezeit A; Mayer G; Greinacher A; Eichler P
Z Orthop Ihre Grenzgeb; 1997; 135(6):543-9. PubMed ID: 9499523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
